HK1052870A1 - 诱导癌细胞死亡和肿瘤消退的方法 - Google Patents

诱导癌细胞死亡和肿瘤消退的方法 Download PDF

Info

Publication number
HK1052870A1
HK1052870A1 HK03105046.0A HK03105046A HK1052870A1 HK 1052870 A1 HK1052870 A1 HK 1052870A1 HK 03105046 A HK03105046 A HK 03105046A HK 1052870 A1 HK1052870 A1 HK 1052870A1
Authority
HK
Hong Kong
Prior art keywords
methods
cell death
cancer cell
tumor regression
inducing cancer
Prior art date
Application number
HK03105046.0A
Other languages
English (en)
Chinese (zh)
Inventor
Q. Daley George
Original Assignee
Q. Daley George
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Q. Daley George filed Critical Q. Daley George
Publication of HK1052870A1 publication Critical patent/HK1052870A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK03105046.0A 2000-10-05 2001-10-05 诱导癌细胞死亡和肿瘤消退的方法 HK1052870A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23824000P 2000-10-05 2000-10-05
US60/238,240 2000-10-05
PCT/US2001/042509 WO2002028381A2 (en) 2000-10-05 2001-10-05 Methods of inducing cancer cell death and tumor regression

Publications (1)

Publication Number Publication Date
HK1052870A1 true HK1052870A1 (zh) 2003-10-03

Family

ID=22897049

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03105046.0A HK1052870A1 (zh) 2000-10-05 2001-10-05 诱导癌细胞死亡和肿瘤消退的方法

Country Status (14)

Country Link
US (1) US6777415B2 (enExample)
EP (1) EP1322334A2 (enExample)
JP (1) JP2004510733A (enExample)
CN (1) CN1479630A (enExample)
AU (2) AU1186202A (enExample)
BR (1) BR0114430A (enExample)
CA (1) CA2424797C (enExample)
HK (1) HK1052870A1 (enExample)
HU (1) HUP0302913A3 (enExample)
MX (1) MXPA03003011A (enExample)
NO (1) NO20031531L (enExample)
NZ (1) NZ524936A (enExample)
WO (1) WO2002028381A2 (enExample)
ZA (1) ZA200302523B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369138B2 (en) 1997-07-11 2002-04-09 Bridgestone Corporation Processability of silica-filled rubber stocks with reduced hysteresis
WO2008109417A1 (en) * 2007-03-02 2008-09-12 Case Western Reserve University Mgmt inhibitor combinations for the treatment of neoplastic disorders
AU2002211427A1 (en) * 2000-10-05 2002-04-15 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
US20040126755A1 (en) * 2001-08-29 2004-07-01 Stephan Dietrich A Gene expression based method for distinguishing metastatic from non-metastatic forms of a tumor, and use in designing therapeutic drugs
HUP0402401A2 (hu) * 2001-11-30 2005-03-29 Schering Corp. Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával
EP1453513A1 (en) * 2001-12-03 2004-09-08 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
US20050004008A1 (en) * 2002-03-01 2005-01-06 Frackelton A. Raymond SHC proteins as therapeutic targets in proliferative diseases
CA2477953A1 (en) * 2002-03-01 2003-09-12 Roger Williams Hospital Shc protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US7691905B2 (en) * 2002-12-24 2010-04-06 New York University Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA)
AU2004289256A1 (en) * 2003-11-06 2005-05-26 Schering Corporation Combination of a farnesyl tranferase inhibitor with an antihormonal agent for the treatment of breast cancer
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
US20070148660A1 (en) * 2005-06-16 2007-06-28 The Regents Of The University Of California Treatment of maladaptive substance use with H-ras antagonists
WO2007042465A2 (en) * 2005-10-07 2007-04-19 Novartis Ag Combinati0n of nilotinib with farnesyl transferase inhibitors
ATE521893T1 (de) * 2005-11-11 2011-09-15 Roger Williams Hospital P66-shc als prädiktiver marker bei der krebsbehandlung
CN102274513B (zh) * 2011-07-06 2013-02-20 南开大学 ERK1/2抑制剂通过刺激巨噬细胞干扰素γ表达抑制肿瘤生长
CN102626416B (zh) * 2012-05-11 2013-04-17 江苏省人民医院 他莫昔芬联合雷帕霉素、人参皂苷Rg3复合物在制备治疗肝癌药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU665341B2 (en) 1990-12-18 1996-01-04 Wellcome Foundation Limited, The Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
EP0906099A4 (en) 1996-04-03 2001-02-07 Merck & Co Inc METHOD FOR TREATING CANCER
JP2000508335A (ja) * 1996-05-30 2000-07-04 メルク エンド カンパニー インコーポレーテッド 癌の治療方法
CA2293706C (en) * 1997-06-17 2008-11-18 Schering Corporation N-substituted urea inhibitors of farnesyl-protein transferase
WO1998057945A1 (en) 1997-06-17 1998-12-23 Schering Corporation Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives as farnesyl protein transferase inhibitors
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
CA2369895C (en) * 1999-01-11 2010-12-21 Princeton University High affinity inhibitors for target validation and uses thereof
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
ES2273688T3 (es) * 1999-04-14 2007-05-16 Dana-Farber Cancer Institute, Inc. Procedimiento y composicion para el tratamiento de cancer.
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US7238525B2 (en) * 2000-06-30 2007-07-03 The Regents Of The University Of California Strategy for leukemia therapy
AU2002211427A1 (en) * 2000-10-05 2002-04-15 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors

Also Published As

Publication number Publication date
US20020128280A1 (en) 2002-09-12
MXPA03003011A (es) 2003-07-14
NO20031531L (no) 2003-06-05
CA2424797A1 (en) 2002-04-11
WO2002028381A3 (en) 2003-03-27
CN1479630A (zh) 2004-03-03
ZA200302523B (en) 2004-08-24
HUP0302913A2 (hu) 2003-12-29
BR0114430A (pt) 2004-01-06
JP2004510733A (ja) 2004-04-08
AU1186202A (en) 2002-04-15
NO20031531D0 (no) 2003-04-04
CA2424797C (en) 2009-12-29
US6777415B2 (en) 2004-08-17
NZ524936A (en) 2005-08-26
HUP0302913A3 (en) 2005-05-30
AU2002211862B2 (en) 2007-03-15
WO2002028381A2 (en) 2002-04-11
EP1322334A2 (en) 2003-07-02

Similar Documents

Publication Publication Date Title
NZ514628A (en) Use of inhibitors for inducing cancer cell death and tumor regression
WO2002028381A3 (en) Methods of inducing cancer cell death and tumor regression
IL138979A0 (en) Use of cannabinoids as anti-inflammatory agents
WO2001064246A3 (en) Farnesyl protein transferase inhibitor combinations with an her2 antibody
EE200000794A (et) Farnesüülproteiintransferaasi inhibiitorite kasutamine radiosensibiliseerimisomadustega farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud kasutamiseks vähi kiiritusravis
ATE200677T1 (de) Substituierte tetra- und pentapeptid hemmstoffe der farnesyl protein transferase
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
WO2001064252A3 (en) Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
PL338555A1 (en) Method of preventing or treating oestrogen-dependent diseases and disorders
WO2001064194A3 (en) Farnesyl protein transferase inhibitor combinations with camptothecin compounds
ES2154693T3 (es) Combinacion de sustancias inductoras de necrosis con sustancias que son activadas por necrosis, para la terapia selectiva de tumores y enfermedades inflamatorias.
ATE415161T1 (de) Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
WO2001064198A3 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
WO2001064218A3 (en) Farnesyl protein transferase inhibitor combinations
WO2001064195A3 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
EA200200808A1 (ru) Модифицированные цитокины, предназначенные для применения в терапии рака
MY137303A (en) Methods for treating proliferative diseases
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
WO2001064197A3 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
IL140716A0 (en) Use of inhibitors of protein kinase c epsilon to treat pain
IS5570A (is) Meðhöndlun á risaeitlingasarkmeini með tálmum viðeitilfrumueiturslóðinni
WO2001091767A3 (en) Compositions for enhancing therapeutic effects containing herbals and/or nutritional supplements and/or minerals and/or vitamins
AU1397901A (en) Therapy with cannabinoids in the treatment of cerebral tumor
WO2002017952A3 (en) Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
WO1998007415A3 (en) Methods for prevention of cellular proliferation and restenosis